company background image
AGH

Althea Group HoldingsASX:AGH Stock Report

Market Cap

AU$81.3m

7D

1.9%

1Y

-44.3%

Updated

18 Oct, 2021

Data

Company Financials +
AGH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AGH Overview

Althea Group Holdings Limited manufactures, sells, and distributes pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, Africa, and Canada.

Price History & Performance

Summary of all time highs, changes and price drops for Althea Group Holdings
Historical stock prices
Current Share PriceAU$0.27
52 Week HighAU$0.23
52 Week LowAU$0.62
Beta1.46
1 Month Change4.85%
3 Month Change-18.18%
1 Year Change-44.33%
3 Year Change-45.46%
5 Year Changen/a
Change since IPO-51.79%

Recent News & Updates

Mar 13
When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?

When Will Althea Group Holdings Limited (ASX:AGH) Become Profitable?

We feel now is a pretty good time to analyse Althea Group Holdings Limited's ( ASX:AGH ) business as it appears the...

Shareholder Returns

AGHAU PharmaceuticalsAU Market
7D1.9%0.04%0.9%
1Y-44.3%-2.4%20.2%

Return vs Industry: AGH underperformed the Australian Pharmaceuticals industry which returned -2.4% over the past year.

Return vs Market: AGH underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is AGH's price volatile compared to industry and market?
AGH volatility
AGH Beta1.46
Industry Beta1.3
Market Beta1

Stable Share Price: AGH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: AGH's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aJosh Feganhttps://www.althea.life

Althea Group Holdings Limited manufactures, sells, and distributes pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, Africa, and Canada. It also offers a range of education, access, and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways through Concierge, an online service, as well as Medic, an online education. In addition, the company provides formulation and manufacturing of recreational cannabis products, such as beverages, edibles, and topicals.

Althea Group Holdings Fundamentals Summary

How do Althea Group Holdings's earnings and revenue compare to its market cap?
AGH fundamental statistics
Market CapAU$81.28m
Earnings (TTM)-AU$15.05m
Revenue (TTM)AU$11.54m

7.2x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AGH income statement (TTM)
RevenueAU$11.54m
Cost of RevenueAU$5.78m
Gross ProfitAU$5.76m
ExpensesAU$20.80m
Earnings-AU$15.05m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.049
Gross Margin49.88%
Net Profit Margin-130.38%
Debt/Equity Ratio0%

How did AGH perform over the long term?

See historical performance and comparison

Valuation

Is Althea Group Holdings undervalued compared to its fair value and its price relative to the market?

1.94x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGH is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: AGH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGH is good value based on its PB Ratio (1.9x) compared to the AU Pharmaceuticals industry average (3.3x).


Future Growth

How is Althea Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

92.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGH's revenue (66.6% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: AGH's revenue (66.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Althea Group Holdings performed over the past 5 years?

-1.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AGH is currently unprofitable.

Growing Profit Margin: AGH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AGH's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AGH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: AGH has a negative Return on Equity (-35.24%), as it is currently unprofitable.


Financial Health

How is Althea Group Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: AGH's short term assets (A$14.9M) exceed its short term liabilities (A$6.8M).

Long Term Liabilities: AGH's short term assets (A$14.9M) exceed its long term liabilities (A$4.5M).


Debt to Equity History and Analysis

Debt Level: AGH is debt free.

Reducing Debt: AGH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AGH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 42.3% each year


Dividend

What is Althea Group Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average board tenure


CEO

Josh Fegan

no data

Tenure

AU$1,466,249

Compensation

Mr. Joshua Fegan also known as Josh, serves as Chief Executive Officer and Managing Director at Althea Group Holdings Limited and serves Executive Director since June 21, 2018. Mr. Fegan serves as Chief Ex...


CEO Compensation Analysis

Compensation vs Market: Josh's total compensation ($USD1.09M) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Josh's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: AGH's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.5%.


Top Shareholders

Company Information

Althea Group Holdings Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Althea Group Holdings Limited
  • Ticker: AGH
  • Exchange: ASX
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$81.282m
  • Shares outstanding: 306.73m
  • Website: https://www.althea.life

Location

  • Althea Group Holdings Limited
  • 360 Elizabeth Street
  • Suite 2
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 07:01
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.